Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer.
about
Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group.S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.Current treatment and clinical trials in ovarian cancer.
P2860
Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Using the expected survival to ...... se in advanced ovarian cancer.
@en
Using the expected survival to ...... se in advanced ovarian cancer.
@nl
type
label
Using the expected survival to ...... se in advanced ovarian cancer.
@en
Using the expected survival to ...... se in advanced ovarian cancer.
@nl
prefLabel
Using the expected survival to ...... se in advanced ovarian cancer.
@en
Using the expected survival to ...... se in advanced ovarian cancer.
@nl
P2093
P356
P1476
Using the expected survival to ...... se in advanced ovarian cancer.
@en
P2093
Chris Williams
George Omura
International Collaborative Ovarian Neoplasm Collaborators
Jan Vermorken
Mahesh Parmar
Marc Buyse
Nicoletta Colombo
Ovarian Cancer Meta-Analysis Project
Valter Torri
P304
P356
10.1200/JCO.2003.04.088
P407
P577
2003-05-01T00:00:00Z